DIANE GLENDINNING: Open Payments
NPI 1710253612 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$24,182 in 56 payments from 13 companies in 2025. Trend: 2023 $526 · 2024 $698 · 2025 $24,182
Speaker / faculty: $18,615Travel & lodging: $3,560Food & beverage: $1,121Consulting: $870Education: $16
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 36 | $23,858 |
| Novartis Pharmaceuticals Corporation | 7 | $102 |
| Immunocore Limited | 2 | $32 |
| PFIZER INC. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| GENZYME CORPORATION | 1 | $18 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
Products named: RYBREVANT, DARZALEX, TECVAYLI, KISQALI, SCEMBLIX, CARVYKTI, KIMMTRAK, ELREXFIO.
Industry payments across AR — which companies pay providers there.
